|  |
| --- |
| Competency Evaluation Tool for  Clozapine (Clozaril) Therapy Training |

|  |  |  |  |
| --- | --- | --- | --- |
| **Trainer’s Printed Name:** | | **Date:** | |
| **Trainer’s Signature:** | | **Trainer’s Contact Information:** | |
| **Clozapine (Clozaril) Therapy Training Guidelines** | | | |
| *Clozapine Training must be completed by a Qualified Trainer.* | | | |
| **Training Components and Procedure** | | | **Comments** |
| **At the conclusion of this training, the Certified staff:** | | |  |
| 1. | Knows where to locate the Service Provider’s Policy that outlines the procedure to follow when an individual is receiving Clozapine Therapy, and who will be responsible for administering Clozapine. | |  |
| 2. | Knows the procedure for obtaining Clozapine Health Care Provider (HCP) Orders, HCP Telephone Orders, HCP Telehealth Orders, and administering Clozapine according to MAP Regulations, Policies, and Curriculum. | |  |
| 3. | Knows that only licensed nurses and Trained Certified staff may administer Clozapine. | |  |
| 4. | Knows that the generic named product ‘Clozapine’ (also known by the common brand name CLOZARIL®) is typically prescribed for the management of individuals diagnosed with schizophrenia and/or schizoaffective disorder. | |  |
| 5. | Knows there is a significant risk of a potentially life threatening blood disorder (agranulocytosis) associated with the use of Clozapine; however, when discovered early, it can be reversed. | |  |
| 6. | Knows that the HCP may order regular Absolute Neutrophil Count (ANC) blood tests to monitor for signs of agranulocytosis. | |  |
| 7. | Knows adverse effects of Clozapine Therapy. | |  |
| 8. | Knows to report any signs or symptoms of infection (e.g., fever, weakness, lethargy, or sore throat) to the HCP. | |  |
| 9. | Knows that individuals diagnosed with schizophrenia or schizoaffective disorder may exhibit suicidal behavior, which refers to actions by the individual that put them at risk for death or serious harm. | |  |
| 10. | Knows that Clozapine Therapy education should be provided (both initial and continuous) for an individual learning to self-administer Clozapine. | |  |
| 11. | Knows that when Clozapine therapy is started, the dose will be low and then slowly increased over time until the therapeutic dose is reached. | |  |
| 12. | Knows if a single dose of Clozapine is missed to contact the MAP Consultant. | |  |
| 13. | Knows if the Clozapine dose is missed for more than two (2) days to not administer the next dose of Clozapine without first contacting the prescribing HCP (authorized prescriber). | |  |
| 14. | Knows how changes are communicated to all staff (e.g., medication progress note, narrative note, flow sheet, etc.). | |  |
| 15. | Knows when and how to contact the individual’s Health Care Provider and/or the MAP Consultant for any Clozapine related issues, questions, or concerns. | |  |
| 16. | Knows when notification or contact with the HCP is necessary. | |  |
| 17. | Knows when a 911 telephone call is necessary. | |  |
| 18. | Knows after Emergency Response personnel arrive and the individual is cared for, to notify appropriate persons, and follow all emergency procedures per the Service Provider’s Policy. | |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Based on the Training Guidelines for Clozapine Therapy, I, as Trainer, have determined that the Certified staff named below have the knowledge to administer Clozapine. | | | | |
|  | | | | |
|  | | Certified Staff’s Printed Name: | Certified Staff’s Signature: | |
| 1. | |  |  | |
| 2. | |  |  | |
| 3. | |  |  | |
| 4. | |  |  | |
| 5. | |  |  | |
| 6. | |  |  | |
| 7. | |  |  | |
| 8. | |  |  | |
| 9. | |  |  | |
| 10. | |  |  | |
| 11. | |  |  | |
| 12. | |  |  | |
| 13. | |  |  | |
| 14. | |  |  | |
| 15. | |  |  | |
| 16. | |  |  | |
| 17. | |  |  | |
| 18. | |  |  | |
| 19. | |  |  | |
| 20. | |  |  | |
| **The Trainer should close empty signature spaces upon completion of the training.** | | | | |
|  | | |